The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy.
S. Gori
No relevant relationships to disclose
F. Montemurro
No relevant relationships to disclose
S. Spazzapan
No relevant relationships to disclose
G. Metro
No relevant relationships to disclose
J. Foglietta
No relevant relationships to disclose
G. Bisagni
No relevant relationships to disclose
A. Ferzi
No relevant relationships to disclose
R. R. Silva
No relevant relationships to disclose
T. Gamucci
No relevant relationships to disclose
M. Clavarezza
No relevant relationships to disclose
L. Stocchi
No relevant relationships to disclose
A. Fabi
No relevant relationships to disclose
F. Cognetti
No relevant relationships to disclose
E. Torrisi
No relevant relationships to disclose
D. Crivellari
No relevant relationships to disclose